Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Issue 8 (24th December 2014)

• Record Type: Journal Article
• Authors: Haidry, R J; Butt, M A; Dunn, J M; Gupta, A; Lipman, G; Smart, H L; Bhandari, P; Smith, L; Willert, R; Fullarton, G; Di Pietro, M; Gordon, C; Penman, I; Barr, H; Patel, P; Kapoor, N; Hoare, J; Narayanasamy, R; Ang, Y; Veitch, A; Ragunath, K; Novelli, M; Lovat, L B
• Other Names: author non-byline.; Banks Matthew author non-byline.; Sehgal Vinay author non-byline.; Graham David author non-byline.; Sweis Rami author non-byline.; Miah Haroon author non-byline.; Morris Danielle author non-byline.; Morris John author non-byline.; Boger Philip author non-byline.; O'Toole Dermot author non-byline.; Cheong Edward author non-byline.; Direkze Natalie author non-byline.; Dhar Anjan author non-byline.; Nylander David author non-byline.; Mahon Brinder author non-byline.
• Is Part Of: Gut. Volume 64:Issue 8(2015)
• Page Start: 1192
• Page End: 1199
• Publication Date: 2014-12-24
• Subjects: BARRETT'S OESOPHAGUS -- OESOPHAGEAL CANCER -- ENDOSCOPIC PROCEDURES; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2014-308501
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Background: Barrett's oesophagus (BE) is a pre-malignant condition leading to oesophageal adenocarcinoma (OAC). Treatment of neoplasia at an early stage is desirable. Combined endoscopic mucosal resection (EMR) followed by radiofrequency ablation (RFA) is an alternative to surgery for patients with BE-related neoplasia. Methods: We examined prospective data from the UK registry of patients undergoing RFA/EMR for BE-related neoplasia from 2008 to 2013. Before RFA, visible lesions were removed by EMR. Thereafter, patients had RFA 3-monthly until all BE was ablated or cancer developed (endpoints). End of treatment biopsies were recommended at around 12 months from first RFA treatment or when endpoints were reached. Outcomes for clearance of dysplasia (CR-D) and BE (CR-IM) at end of treatment were assessed over two time periods (2008–2010 and 2011–2013). Durability of successful treatment and progression to OAC were also evaluated. Results: 508 patients have completed treatment. CR-D and CR-IM improved significantly between the former and later time periods, from 77% and 56% to 92% and 83%, respectively (p<0.0001). EMR for visible lesions prior to RFA increased from 48% to 60% (p=0.013). Rescue EMR after RFA decreased from 13% to 2% (p<0.0001). Progression to OAC at 12 months is not significantly different (3.6% vs 2.1%, p=0.51). Conclusions: Clinical outcomes for BE neoplasia have improved significantly over the past 6 years with improved lesion recognition and aggressive resection of visible lesions before RFA. Despite advances in technique, the rate of cancer progression remains 2–4% at 1 year in these high-risk patients. Trial registration number: ISRCTN93069556.